Atalanta Therapeutics has bagged $97 million, money the biotech plans to use to launch clinical trials for its small ...

TG Therapeutics exceeded 2024 revenue guidance by 24%, signaling strong growth. Read more to see why I rate TGTX stock a ...

In years past, crossbow manufacturers focused on increasing bolt speed while minimizing costs. Though speed is still a focal point for new crossbows, a few other trends emerged in 2025.

SEATTLE, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective," the "Company," “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a ...

A live webcast of the Company’s presentation may be accessed under “News and Events” in the Investors section of the Dianthus Therapeutics website. Dianthus Therapeutics is a clinical-stage ...

ZUG, Switzerland and BOSTON – CRISPR Therapeutics (NASDAQ:CRSP), a leader in gene-based medicine development, announced today its intention to appoint Briggs Morrison, M.D., to its Board of Directors ...

ZUG, Switzerland and BOSTON, Jan. 07, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...

Morrison currently serves as CEO and as a member of the Board of Directors of Crossbow Therapeutics. TipRanks is the most comprehensive data set of sell side analysts and hedge fund managers.